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The tumor suppressor Smad4/DPC 4 as a central mediator of
Smad function
Ying Zhang*, Thomas Musci† and Rik Derynck*
Background: The invertebrate and vertebrate Smad proteins have recently been
identified as important mediators of the responses to transforming growth factor
b (TGF-b) and related factors. We have previously shown that Smad3 and
Smad4 (the product of the tumor suppressor gene DPC 4) strongly synergize as
mediators of TGF-b signaling, and that inactive carboxy-terminally truncated
mutants of either Smad act as dominant-negative inhibitors of the natural TGF-b
response. The finding that Smad4, unlike Smad3, does not interact with the
TGF-b receptor, coupled with the distinct structural features of Smad4, raises
the possibility that Smad4 cooperates not only with Smad3, but also with Smad1
and Smad2 to mediate signaling by TGF-b family members.
Results: Overexpression of Smad4 in ‘animal caps’ taken from Xenopus
embryos induced both ventral and dorsal mesoderm, thereby mimicking the
effects of TGF-b family members — bone morphogenetic protein-2 (BMP-2) or
BMP-4 and activin, respectively. Low levels of Smad4 mRNA coinjected with
Smad1 or Smad2 mRNA also synergized to induce ventral or dorsal mesoderm,
respectively. In addition, Smad4 synergized with Smad2, as it does with Smad3,
to induce gene expression from the promoter for plasminogen activator inhibitor-
1. The carboxy-terminal domains of both Smad3 and Smad4 were required for
this synergy. Finally, a short carboxy-terminal truncation of Smad4, previously
identified as a mutation of DPC 4 in tumors, blocked nuclear translocation of
wild-type Smads 1, 2, 3 and 4, consistent with our observation of a physical
interaction between truncated Smad4 and the other Smads. 
Conclusions: Our observations indicate that Smad4 cooperates with Smad1,
Smad2 and Smad3 to act as a common mediator of signaling by TGF-b-related
factors, and provide a mechanism that explains the dominant-negative
interference with receptor signaling that results from expression of the naturally
occurring Smad4/DPC 4 truncation mutant.
Background
The transforming growth factor-b (TGF-b) superfamily
comprises various secreted polypeptides which regulate
cell growth and differentiation and tissue morphogenesis
in many organisms [1]. TGF-b and related factors, includ-
ing activin and the bone morphogenetic proteins (BMPs),
signal by interacting with two types of receptors that have
serine/threonine kinase activity: type I and type II recep-
tors, which form a heteromeric receptor complex [2,3].
Recently, genetic approaches in Drosophila and Caenorhab-
ditis elegans and complementary biochemical and develop-
mental studies in vertebrates have resulted in the
characterization of Mad (Mothers against Decapenta-
plegic) in Drosophila, Sma in C. elegans, and their verte-
brate homologs Smads, as important signaling mediators of
the response to TGF-b-related factors [3,4]. All Smads
show conserved amino-terminal and carboxy-terminal
domains, separated by a long proline-rich ‘linker’ segment
of variable length and sequence [4]. 
The results of studies in which Smad proteins were over-
expressed have been used to suggest that different Smads
induce distinct responses that mimic the natural receptor-
mediated responses to different ligands. Xenopus Smad1 or
human Smad1 are likely to be mediators of BMP-2/BMP-4
signals [5–7], having similar roles to that of Mad in
Decapentaplegic signaling [8], whereas Smad2 may
mediate activin signaling [5,9]. We have shown previously
that Smad3 and Smad4 (originally identified as the
product of the candidate tumor suppressor gene DPC 4
[10]) strongly synergize to induce TGF-b-like responses,
and function as mediators of TGF-b signaling [11].
Accordingly, inactive carboxy-terminal truncation mutants
of either Smad3 or Smad4 can block natural TGF-b
responses, indicating that both proteins are required for
TGF-b signaling. In contrast to Smad3, however, Smad4
does not associate with the TGF-b receptor complex and
is not phosphorylated, suggesting that Smad4 functions
differently from Smad3 and might act downstream from
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Smad3. The amino-acid sequences of the Smads also indi-
cate that Smad4 is quite distinct, having a characteristic
insert in the conserved carboxy-terminal domain and a
considerably larger size than Smad1, Smad2 and Smad3,
which are more closely related to each other. The coopera-
tivity of Smad4 with Smad3, its distinct structure, and its
lack of receptor association raise the possibility that
Smad4 may also cooperate with Smad1 and Smad2 to
mediate signaling by BMP-2/BMP-4 or activin, respec-
tively; in this way, Smad4 may function as a common
mediator of signaling by TGF-b-related factors. 
Results and discussion
Smad4/DPC 4 synergizes with Smad1 and Smad2
If Smad4 cooperates with Smad1 or Smad2, then we
would predict that Smad4 synergizes with Smad1 to
induce a BMP-2/BMP-4-like response, and with Smad2
to induce an activin-like response, by analogy to the
observed synergy of Smad4 with Smad3 to induce a
TGF-b-like response [11]. We tested this hypothesis by
using the Xenopus ‘animal cap’ assay in which a piece of
animal pole explant, capable of responding to an inducing
signal by developing into mesoderm, is cultured with
potential inducing factors and the resulting tissue ana-
lyzed. Consistent with previous findings [5,7,9,12],
microinjection of mRNA encoding either BMP-4 or
Smad1 induced ventral mesoderm, as assessed by the
induction of globin mRNA expression (Fig. 1a). In con-
trast, treatment of the animal caps with activin or injec-
tion of Smad2 mRNA induced muscle actin mRNA
expression, a marker of dorsal mesoderm (Fig. 1a). If
Smad4 synergizes with endogenous Smad1 and Smad2 to
mediate ligand-independent BMP-2/BMP-4 and activin
signaling, then injection of Smad4 mRNA would be
expected to induce both ventral and dorsal mesoderm.
This was indeed the case, as injection of Smad4 mRNA
induced expression of both the ventral mesoderm marker
globin and the dorsal mesoderm marker muscle actin in
Xenopus animal cap assays (Fig. 1a). Thus, Smad4 induced
both ventral and dorsal mesoderm, mimicking the effects
of BMP-2/BMP-4 and activin/TGF-b. 
We also injected small amounts of Smad1 or Smad4
mRNA, or both of them together. As shown in Figure 1b,
each of the injected mRNAs by itself was not sufficient to
induce considerable expression of the ventral mesoderm
marker globin. When injected together, however, they
acted synergistically to strongly induce globin expression.
Similarly, when compared to the effects of Smad2 or
Smad4 mRNA alone, it could be seen that low levels of
Smad2 and Smad4 mRNA also synergized to induce
increased expression of muscle actin, a marker of dorsal
mesoderm differentiation (Fig. 1b). 
To further evaluate the cooperativity of Smad4 with
Smad1, Smad2 and Smad3, we tested the ability of the
Smads to induce luciferase expression from the promoter
for plasminogen activator inhibitor-1 (PAI-1). We have
previously shown that Smad3 and Smad4 each induce a
low level of luciferase expression in the PAI-1 luciferase
assay, and that they dramatically synergize to induce a
20-fold to 30-fold increase in luciferase expression (Fig.
2) [11]. Similarly, Smad4 coexpression with Smad2
resulted in a strong synergy in inducing luciferase
expression, although Smad2 by itself did not induce
detectable expression. Coexpression of Smad1 and
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Figure 1
Synergy of Smad4 with Smad1 and Smad2 in inducing ventral and
dorsal mesoderm in Xenopus animal caps. (a) Overexpression of
Smad4 induces both ventral and dorsal mesoderm in Xenopus animal
caps. Gene expression was assayed by amplification of the mRNAs
using a reverse transcriptase coupled polymerase chain reaction (RT-
PCR), and the 32P-labeled DNA fragments were analyzed by gel
electrophoresis. Microinjection of BMP-4 mRNA (1 ng) or Smad1
mRNA (2 ng) induced the expression of globin mRNA, a ventral
mesoderm marker. Treatment with 15 ng ml–1 activin A or
microinjection of 2 ng Smad2 mRNA induced the expression of muscle
actin mRNA, a marker for dorsal mesoderm. Finally, injection of 2 ng
Smad4 mRNA induced both globin and muscle actin mRNA. N-CAM
mRNA is a marker for neural tissue. (b) Smad4 synergizes with Smad1
or Smad2 to induce ventral or dorsal mesoderm, respectively.
Coinjection of Smad1 mRNA (0.4 ng) and Smad4 mRNA (0.2 ng)
induced expression of globin. Coinjection of Smad2 mRNA (0.1 ng)
and Smad4 mRNA (0.1 ng) induced strong expression of muscle actin.
EF-1a mRNA is ubiquitously expressed and serves as a control for the
quantity of mRNA in each assay. Uninjected animal caps were also
tested in each case (labeled ‘control’), and the positive control
(embryo) corresponds to whole embryo RNA; the negative control
(–RT) corresponds to embryonic RNA subjected to RT-PCR without
the addition of reverse transcriptase.
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Smad4 did not induce a luciferase response, consistent
with the lack of sensitivity of this reporter assay to BMP-
2/BMP-4 (Fig. 2). 
The biological activities of Smad3 and Smad4 require their
conserved carboxy-terminal domains
In order to determine which domains are required for
synergy between Smads, we constructed expression plas-
mids for the segments of Smad3 and Smad4 shown in
Figure 3a. Western blot analyses of transfected cell lysates
revealed that these Smad3 and Smad4 segments, as well
as the full-size proteins, were stably expressed (Fig. 3c).
Using the PAI-1 luciferase construct as a reporter system,
we found that the synergy between Smad3 and Smad4
was associated with the conserved carboxy-terminal
domains of both Smads (Fig. 3b). We have also recently
shown that these carboxy-terminal domains mediate
homomeric and heteromeric interactions of Smad3 and
Smad4 [13]. Thus, coexpression of Smad4 with the
carboxy-terminal domain of Smad3, with or without
Smad3’s proline-rich linker segment, resulted in a similar
synergistic response to that obtained with full-size Smad3
and Smad4 (Fig. 3b, lanes 7 and 8). This result is consis-
tent with the ability of the Smad2 carboxy-terminal
domain to induce dorsal mesoderm, although in the
animal cap assay the response obtained with the carboxyl
terminus exceeded the response with full-size Smad2 [9].
The same carboxy-terminal domain in Smad1 also dis-
plays transcriptional activity when fused to a GAL4
binding domain that allows association with DNA [7].
Conversely, the carboxy-terminal domain of Smad4, with
the Smad4 proline-rich linker sequence, also synergized
with full-size Smad3 (Fig. 3b, lane 11), further confirming
that the signaling activity of Smads is associated with
their conserved carboxy-terminal domains. However,
coexpression of full-size Smad3 and the carboxy-terminal
domain of Smad4 without its proline-rich linker
(Smad4C294) resulted in a very low activity (Fig. 3b, lane
13). It has been reported that the carboxy-terminal
domain of Smad4 is constitutively active in a transcription
assay when fused to a GAL4 DNA-binding domain [7].
As the truncated Smad4 domain used in the transcription
assay extends 28 amino acids further at its amino termi-
nus than Smad4C294, we designed another variant of the
Smad4 carboxy-terminal domain, Smad4C266, which is
identical to the truncated Smad4 domain that was used in
the transcription assay [7]. In contrast to Smad4C294,
Smad4C266 strongly synergized with full-size Smad3 in
the PAI-1 luciferase assay (Fig. 3b, lane 12). This result
indicates that the 28 additional amino acids that are not
incorporated in Smad4C294 are required for the synergis-
tic activity of Smad4 with Smad3. It is indeed possible
that they play a role in stabilizing the homomeric interac-
tions of Smad4 or the heteromeric interactions with
Smad3, as both homomeric and heteromeric interactions
between Smad3 and Smad4 are required for full biologi-
cal activity [13]. 
Remarkably, coexpression of the carboxy-terminal
domains of Smad3 and Smad4, with or without their
proline-rich upstream sequences, did not result in
luciferase expression (Fig. 3b, lanes 14 and 15), suggesting
that sequences in the amino-terminal conserved domains
are required for the activity of the carboxy-terminal
domains or for the homomeric and heteromeric interac-
tions. Taken together, these findings also suggest that the
ability of the Smad2 carboxy-terminal domain to induce
dorsal mesoderm in Xenopus animal caps [9] may be due to
an interaction with endogenous Smad4.
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Figure 2
Smad2 and Smad3 synergize with Smad4 to induce luciferase
expression from the PAI-1 promoter. The induction of luciferase
expression is presented relative to control (pRK5) transfected
SW480.7 cells in the absence of ligand — TGF-b or activin. Although
Smad2 by itself does not increase luciferase activity (lane 3), Smad2
and Smad4 synergize to induce luciferase expression (lane 7),
comparable to the synergy of Smad3 and Smad4 (lane 8).
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Role of the Smad4 carboxyl terminus in nuclear
translocation
The proposed role of Smads as transcriptional mediators is
consistent with their localization to the nucleus. Indeed,
Smads have been localized by immunofluorescence to
both the cytoplasm and the nucleus, and the fraction of
Smad proteins in the nucleus can be increased by signal-
ing through their associated receptors [6,7,9]. We thus
evaluated the nuclear localization of all four Smad proteins
in transfected COS-1 cells using immunofluorescence.
Smad1 and Smad2 were distributed in both the cytoplasm
and nucleus of transfected cells (Fig. 4a,b), consistent with
previous findings [6,7,9], whereas Smad3 and Smad4 were
predominantly localized to the nucleus (Fig. 4c,d). Treat-
ment of Smad3- or Smad4-overexpressing cells with TGF-
b, activin or BMP-2, or coexpression with a constitutively
active Thr204→Asp mutant of the type I TGF-b receptor,
did not affect nuclear localization (data not shown). 
We next examined the subcellular localization of different
Smad proteins with short carboxy-terminal truncations. A
carboxy-terminal truncation of only 39 amino acids inacti-
vates Mad function in Drosophila [14], and the correspond-
ing mutation has been found in the Smad4/DPC 4 gene in
pancreatic carcinomas where it is thought to inactivate the
tumor suppressor function of Smad4/DPC 4 [10]. Similar
deletions in Smad3 and Smad4 not only inactivate them
but also confer dominant-negative interference with the
endogenous Smad activity required for TGF-b signaling
[11]. As shown in Figure 4e–g, there was no detectable
effect of these short carboxy-terminal truncations of
Smad1, Smad2 and Smad3 on their subcellular localization.
Surprisingly, the same carboxy-terminal deletion pre-
vented nuclear localization of Smad4: the Smad4∆c
mutant was localized in the cytoplasm without any
detectable immunofluorescence in the nucleus (Fig. 4h).
The inability of Smad4∆c to translocate into the nucleus
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Figure 3
Synergy between Smad3 and Smad4 requires
the conserved carboxy-terminal domains. 
(a) A schematic diagram of Smad3 and
Smad4 derivative proteins, with the amino-
terminal (dark gray) and carboxy-terminal (light
gray) conserved domains marked; numbers
mark the amino acid positions. (b) The
induction of luciferase expression from the
PAI-1 promoter in transfected SW480.7 cells
by Smads and their derivatives. The values are
relative to control (pRK5) transfected cells in
the absence of ligand. (c) The expression of
Smad3, Smad4 and their derivatives were
assayed by separating transfected COS-1 cell
lysates by SDS–PAGE and immunoblotting
using the anti-FLAG M2 antibody that
recognizes the different Smads and
derivatives. Besides the major protein
product, Smad3C and Smad4C266 each
also show a smaller degradation product.
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distinguishes Smad4 from Smad1, Smad2 and Smad3.
Remarkably, the carboxy-terminal deleted sequence does
not contain a recognizable nuclear translocation signal [15].
As the carboxy-terminally truncated form of Smad4 func-
tions as a dominant-negative inhibitor of TGF-b signaling,
and considering the functional cooperativity and het-
eromeric physical affinity between Smad4 and Smad1,
Smad2 and Smad3 [13], we evaluated whether coexpres-
sion of Smad4Dc would affect the subcellular localization
of full-size Smad1, Smad2 and Smad3. As shown in Figure
4i–l, overexpression of Smad4Dc prevented nuclear local-
ization of wild-type Smad1, Smad2, Smad3 and Smad4. In
Smad4Dc-producing cells, a coexpressed immunotagged
cyclin B1 with an attached nuclear localization sequence
was appropriately translocated into the nucleus (data not
shown). These findings provide additional evidence for
the functional cooperation of Smad4 with Smad1, Smad2
and Smad3, and strongly support a physical heteromeric
interactions between Smad4Dc with these full-size Smad
proteins. Such interactions would be consistent with the
heteromeric and homomeric associations observed in yeast
two-hybrid assays [11,13]. Accordingly, immunoprecipita-
tion of Smad1, Smad2, Smad3 or Smad4 resulted in copre-
cipitation of coexpressed Smad4Dc in transfected COS-1
cells (Fig. 4m–o). 
The observed ability of the mutant Smad4, as a result of its
short carboxy-terminal deletion, to prevent nuclear translo-
cation of Smad1, Smad2 and Smad3, and the physical het-
eromeric interaction between Smad4Dc and these Smads
may explain the potent ability of Smad4Dc to function as a
dominant-negative mutant. This same deletion also inacti-
vates the function of Smad4/DPC 4 as a suppressor of pan-
creatic carcinomas [10]. Because Smad3Dc is still able to
translocate into the nucleus, yet acts as a dominant-negative
274 Current Biology, Vol 7 No 4
Figure 4
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(a–l) The carboxy-terminal truncation mutant Smad4Dc is not
translocated into the nucleus and blocks nuclear transport of wild-type
Smad1, Smad2, Smad3 and Smad4. Transfected COS-1 cells
expressing the indicated FLAG-tagged (F) Smads were stained for
Smad expression by immunofluorescence using the anti-FLAG antibody
M2 and fluorescein isothyocyanate conjugated secondary antibody.
(a–d) Full-size Smad1 and Smad2 were localized to both the cytoplasm
and nucleus, whereas Smad3 and Smad4 were predominantly localized
to the nucleus. (e–h) The carboxy-terminal truncation (Dc) does not
affect cellular localization of Smad1, Smad2 or Smad3, but prevents
nuclear translocation of Smad4. (i–l) Nuclear localization of FLAG-
tagged, wild-type Smad1, Smad2, Smad3 and Smad4 is blocked when
they are coexpressed with Myc-tagged (M) Smad4Dc. Immunostaining
of the FLAG-tagged, full-size Smads is shown. (m–o) Smad4Dc
interacts with full-size Smad1, Smad2, Smad3 and Smad4. COS-1 cells
were transfected with expression plasmids for Myc-tagged (M) full-size
Smad1, Smad2, Smad3 or Smad4 (1mg), and/or FLAG-tagged (F)
Smad4Dc (2 mg). (m) Immunoblotting of cell lysates using the anti-FLAG
antibody revealed expression of Smad4Dc. Immunoprecipitation (IP)
using the anti-Myc antibody revealed not only (n) precipitation of Myc-
tagged Smad1, Smad2, Smad3 or Smad4 by subsequent
immunoblotting for the Myc tag, but also (o, lanes 1–9) coprecipitation of
Smad4Dc as assessed by subsequent immunoblotting for the FLAG tag.
(o, lane 10) Immunoprecipitation using the anti-Flag antibody followed by
subsequent immunoblotting with the same antibody. Considering that it
is not possible to perform quantitative coprecipitations, it is unclear how
stable the interactions are or what fraction of Smad4Dc coprecipitates.
Expressing Myc-tagged Smad4 resulted in the appearance of a low
molecular weight immunoreactive band as well as the full-size protein
(seen in n), which is presumably a degradation product.
inhibitor of Smad activity and TGF-b signaling [11], it
may act through a different mechanism to inhibit TGF-b
signaling.
The ability of both the full-size and the carboxy-terminal
truncated forms of Smad1, Smad2 and Smad3 to translocate
into the nucleus is in striking contrast to the behavior of
Smad4, and raises the possibility that a second nuclear
translocation sequence or motif may be located upstream of
the conserved carboxy-terminal domain in Smad1, Smad2
and Smad3. We therefore assessed, by immunofluores-
cence, the ability of the carboxy-terminal domain of Smad3,
with or without the short carboxy-terminal deletion, as well
as the ability of several other Smad3 truncation mutants
(see Fig. 3a) to localize to the nucleus. As shown in Figure
5d, the conserved carboxy-terminal segment of Smad3,
expressed by itself, translocated into the nucleus of trans-
fected cells. In contrast, the same conserved domain con-
taining the carboxy-terminal 43 amino-acid deletion was not
able to translocate into the nucleus (Fig. 5e). This result,
and the inability of Smad4Dc to translocate into the
nucleus, suggests that the conserved carboxy-terminal
domains of the Smads may contain an as yet unidentified
nuclear localization sequence, and that Smad3, and presum-
ably Smad1 and Smad2 but not Smad4, contain a second
nuclear localization sequence upstream from the conserved
carboxy-terminal domain. This second nuclear localization
sequence is most likely to be located in the proline-rich
linker region, as the amino-terminal domain of Smad3 with
the Smad3 linker sequence, but not the amino-terminal
domain alone, translocated into the nucleus (Fig. 5a,b).
Taken together, our current findings provide evidence for
a function of Smad4 as a common mediator of Smad
activity and receptor signaling by TGF-b-related factors.
In contrast to Smad1, Smad2 and Smad3 which are
phosphorylated and may be direct substrates for the
receptors’ kinase activity [6,11,16], Smad4 is not phospho-
rylated or receptor-associated. Smad4 cooperates function-
ally with Smad1, Smad2 and Smad3, as illustrated by its
synergistic activity with these Smads and the ability of
Smad4Dc to block their nuclear translocation. Further-
more, the role of the short carboxy-terminal sequence of
Smad4 in nuclear translocation is remarkable, especially as
deleting the corresponding sequences in Smad1, Smad2
and Smad3 does not interfere with their nuclear trans-
location. This suggests the presence of an additional
upstream nuclear translocation sequence or motif in these
Smads, which is likely to be located in the linker domain.
Further studies will be required to characterize the struc-
tural requirements, and to identify the mechanism of
nuclear translocation, of Smad4 as well as of the other
Smad proteins.
Following submission of this manuscript, Lagna et al. [17]
also showed that Smad4/DPC 4 cooperates with Smad1
and Smad2 in Xenopus animal cap assays and synergizes
with Smad2 in an assay for gene induction using 3TP–lux
as a reporter. Their findings and ours are in agreement. 
Materials and methods
Plasmids
The mammalian expression plasmids for wild-type Smad1, Smad2,
Smad3 and Smad4 and the carboxy-terminal truncated mutants
Smad1Dc, Smad2Dc, Smad3Dc and Smad4Dc have been described
previously [11]. DNA fragments for defined Smad segments were gen-
erated by PCR amplification and flanked with 5′ EcoRI or BamHI and
3′ SalI sites, and subsequently subcloned into the pRK5F plasmid [18],
thereby introducing a carboxy-terminal FLAG tag to the expressed pro-
teins. Detailed descriptions of how the individual expression plasmids
for the various Smad mutants were generated can be obtained upon
request.
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Figure 5
(a) Smad3NF Smad3NLF Smad3LCF Smad3CF Smad3C∆cF(b) (c) (d) (e)
Subcellular localization of Smad3 deletion mutants shows that a 43
amino-acid carboxy-terminal truncation of the conserved carboxy-
terminal domain of Smad3 inhibits its nuclear translocation.
Transfected COS-1 cells expressing FLAG-tagged (F) Smad3
derivatives were stained by immunofluorescence using the anti-FLAG
antibody. (a) The amino-terminal segment of Smad3 (Smad3N)
expressed by itself was localized to only the cytoplasm, whereas (b)
Smad3NL, which contains both the amino-terminal segment and the
proline-rich linker domain, was localized to both the cytoplasm and,
more predominantly, the nucleus. (c,d) The carboxy-terminal domain
with or without the linker domain — Smad3LC and Smad3C,
respectively — also had some cytoplasmic but predominantly nuclear
localization. (e) The same conserved carboxy-terminal Smad3 domain
lacking the carboxy-terminal 43 amino acids (Smad3CDc) was unable
to translocate into the nucleus, however, and this Smad derivative
accumulated around the nucleus. 
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Embryonic mesoderm induction assays
Plasmids of the vector pRK5 containing the full-size coding sequences
for Smad1, Smad2 or Smad4 [11] or for BMP-4 (unpublished) were
linearized with PvuI. Capped mRNA was synthesized from the sp6 pro-
moter using the SP6 mMessage Machine kit (Ambion). Xenopus
embryo animal caps were injected at the 2-cell stage, cut at blastula
stage 8 to early 9 and cultured to late stage 32. Recombinant human
activin A (Lot #15365-36(1)) was obtained through NHPP, NIDDK,
NICHHD, US Drug Administration. RNA was prepared from five caps
or one embryo using Trizol (Life Technologies, Inc.). Globin (ventral
mesoderm), muscle actin (dorsal mesoderm), N-CAM (neural tissue)
and EF-1a (control) mRNAs were assayed by RT-PCR and subsequent
gel electrophoresis of the 32P-labelled PCR products. The RT-PCR
conditions and primer sequences were as described [19,20].
Transient transfections, immuoprecipitations and
immunoblotting
Both 293 and SW480.7 cells, maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum (FBS), were trans-
fected using LipfectAMINE (Life Technologies, Inc.) according to the
manufacturer’s suggestion. Cells were lysed 48 h after transfection in a
lysis buffer (25 mM Tris pH 8.0, 300 mM NaCl, 1% Triton X-100) and
immunoprecipitations were done as described using the anti-FLAG M2
antibody (IBI, Kodak) or anti-Myc 9E2 antibody (J.M. Bishop, UCSF).
Imunoblotting using these antibodies was performed using the ECL kit
(Amersham).
Gene expression reporter assay
TGF-b-inducible and activin-inducible transcription from the PAI-1 pro-
moter in plasmid p800luc [21] was assayed as described [18]. Plasmid
pRKbgal, which expresses b-galactosidase under control of the CMV
promoter [18], was included in all assays to normalize the luciferase
activities for transfection efficiency. Briefly, transfection of SW480.7
cells was carried out in six-well dishes using LipofectAMINE. For each
assay, 1 mg expression plasmid (0.5 mg of a Smad expression plasmid,
supplemented with 0.5 mg pRK5 vector plasmid for single transfections,
0.5 mg p800luc and 0.5 mg pRKbgal were cotransfected. Cells were
treated with or without 5 ng ml–1 TGF-b1 or 12.5 ng ml–1 activin A in
medium containing 0.2% FBS, 12 h after transfection. After 24 h, the
cells were lysed and luciferase activity was measured. 
Immunofluorescence
COS-1 cells were transiently transfected with 0.5–1.0mg of an expres-
sion plasmid for a wild-type Smad or with 5 mg of an expression plasmid
encoding a truncated Smad using LipofectAMINE. Cells were plated
onto Falcon 8 chamber culture slides 24 h after transfection and incu-
bated overnight. Immunofluorescence was performed using anti-FLAG
antibody M2 (1:500 dilution, IBI Kodak) and FITC-conjugated goat anti-
mouse IgG antibody (1:200 dilution, Jackson Immunological Laboratory). 
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